Category | FY | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
Anthrax
|
2012
|
NIAID
|
5R01AI043197-15
|
|
Alternative approaches for NALT-based immunity to respiratory pathogens
|
BOYAKA, PROSPER
|
OHIO STATE UNIVERSITY
|
OH
|
$367,538
|
Anthrax
|
2012
|
NIAID
|
5R01AI070654-05
|
|
Analyzing Anthrox Toxins in Drosophila
|
BIER, ETHAN
|
UNIVERSITY OF CALIFORNIA AT SAN DIEGO
|
CA
|
$371,695
|
Anthrax
|
2012
|
NIAID
|
5R01AI059348-07
|
|
B. anthracis: passive immunization with anticapsular mAb
|
KOZEL, THOMAS
|
UNIVERSITY OF NEVADA RENO
|
NV
|
$541,664
|
Anthrax
|
2012
|
NIAID
|
5R01AI064654-05
|
|
Role of Anthrax Toxin Receptors in Angiogenesis and Endothelium
|
KITAJEWSKI, JAN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$394,490
|
Anthrax
|
2012
|
NIAID
|
5R21AI092313-02
|
|
Role and function of Spx paralogs of Bacillus anthracis
|
ZUBER, PETER
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$193,400
|
Anthrax
|
2012
|
NIAID
|
5R21AI092010-02
|
|
Mechanisms of Anthrax Virulence Factor AtxA.
|
NUDLER, EVGENY
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$211,250
|
Anthrax
|
2012
|
RMAP
|
5R03MH093184-02
|
|
High-throughput multiplex microsphere screening for toxin protease inhibitors
|
GRAVES, STEVEN
|
UNIVERSITY OF NEW MEXICO
|
NM
|
$37,750
|
Anthrax
|
2012
|
NIAID
|
5R21AI092024-02
|
|
Mechanism of spore germination
|
HANNA, PHILIP
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$222,960
|
Anthrax
|
2012
|
NIAID
|
5R01AI076852-05
|
|
Receptor Decoy Inhibitor of Anthrax Toxin
|
YOUNG, JOHN
|
SALK INSTITUTE FOR BIOLOGICAL STUDIES
|
CA
|
$464,225
|
Anthrax
|
2012
|
NIAID
|
5R21AI088329-02
|
|
Optical Imaging to Monitor Heme Acquisition during Bacterial Infection
|
MARESSO, ANTHONY
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$229,484
|
Anthrax
|
2012
|
NIAID
|
5R01AI057472-08
|
|
Isolation of new phage enzymes to kill B. anthracis
|
FISCHETTI, VINCENT
|
ROCKEFELLER UNIVERSITY
|
NY
|
$418,275
|
Anthrax
|
2012
|
NIAID
|
5R01AI090085-02
|
|
CryoEM analysis of Anthrax Toxin Pore Complexes
|
FISHER, MARK
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
KS
|
$375,000
|
Anthrax
|
2012
|
NIAID
|
5U01AI082086-04
|
|
Multivalent Plague, Anthrax Vaccines Using Bacteriophage T4 Display
|
RAO, VENIGALLA
|
CATHOLIC UNIVERSITY OF AMERICA
|
DC
|
$530,345
|
Anthrax
|
2012
|
NIGMS
|
5R01GM043577-24
|
|
Gene Expression During Sporulation
|
PIGGOT, PATRICK
|
TEMPLE UNIVERSITY
|
PA
|
$367,538
|
Anthrax
|
2012
|
NIBIB
|
5R21EB013413-02
|
|
Tunable affinity and heat stable antibody targeting of nanoparticles
|
SULCHEK, TODD
|
GEORGIA INSTITUTE OF TECHNOLOGY
|
GA
|
$177,322
|
Anthrax
|
2012
|
NIGMS
|
2R01GM035370-27
|
|
Genetics of secretion in yeast
|
NOVICK, PETER
|
UNIVERSITY OF CALIFORNIA AT SAN DIEGO
|
CA
|
$415,580
|
Anthrax
|
2012
|
NIAID
|
2R01AI069227-06
|
|
Surface Proteins of Bacillus anthracis
|
SCHNEEWIND, OLAF
|
UNIVERSITY OF CHICAGO
|
IL
|
$384,624
|
Anthrax
|
2012
|
NCI
|
5R21CA152536-02
|
|
Anthrax Toxin Receptor as a marker and target of breast cancer stem cells
|
NAKSHATRI, HARIKRISHNA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
IN
|
$167,475
|
Anthrax
|
2012
|
NIAID
|
1R21AI094564-01A1
|
|
Evaluation of the nasal adjuvant activity of angiotensin peptide Ang-(1-7)
|
STAATS, HERMAN
|
DUKE UNIVERSITY
|
NC
|
$196,250
|
Anthrax
|
2012
|
NIAID
|
1R01AI095488-01A1
|
|
Peptide-Based Quorum Sensing Controlling Virulence in Bacillus anthracis
|
LEE, HYUNWOO
|
UNIVERSITY OF ILLINOIS
|
IL
|
$398,750
|
Anthrax
|
2012
|
NIAID
|
5R01AI093459-02
|
|
IMPDH-targeted antibiotics for select agents
|
HEDSTROM, LIZBETH
|
BRANDEIS UNIVERSITY
|
MA
|
$1,058,736
|
Anthrax
|
2012
|
NIAID
|
5R01AI093365-02
|
|
Immunoassay for capsular antigen for rapid diagnosis of anthrax
|
KOZEL, THOMAS
|
UNIVERSITY OF NEVADA RENO
|
NV
|
$620,422
|
Anthrax
|
2012
|
NIGMS
|
5SC1GM095475-02
|
|
Receptor disulfide allosteric regulation of anthrax toxin action
|
SUN, JIANJUN
|
UNIVERSITY OF TEXAS EL PASO
|
TX
|
$242,320
|
Anthrax
|
2012
|
NIAID
|
5U01AI078048-05
|
|
Countermeasures for Bioterroism Targeting Cellular Host Factors
|
REED, JOHN
|
SANFORD-BURNHAM MEDICAL RESEARCH INSTIT
|
CA
|
$837,768
|
Anthrax
|
2012
|
NIAID
|
5R01AI022021-29
|
|
Molecular Mechanisms of Bacterial Pathogenesis
|
COLLIER, ROBERT
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
MA
|
$758,760
|
Anthrax
|
2012
|
NIAID
|
5F31AI094961-02
|
|
Protective Effects of Anti-BclA Antibodies in Bacillus anthracis Infection
|
RODRIGUEZ BARRANTES, JUAN
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$34,094
|
Anthrax
|
2012
|
NIAID
|
5R01AI093397-02
|
|
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against
|
YU, LLOYD
|
PLANET BIOTECHNOLOGY, INC.
|
CA
|
$1,166,055
|
Anthrax
|
2012
|
NIAID
|
5U01AI077989-05
|
|
Protection Against Inhalation Anthrax with Inactivated Spores
|
GUINEY, DONALD
|
UNIVERSITY OF CALIFORNIA AT SAN DIEGO
|
CA
|
$1,017,835
|
Anthrax
|
2012
|
NIAID
|
5R01AI077644-03
|
|
Chemical Strategies to Manipulate A1-2 Signaling in Bacterial Pathogens
|
JANDA, KIM
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$470,003
|
Anthrax
|
2012
|
NEI
|
5R01EY018829-05
|
|
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors
|
ROGERS, MICHAEL
|
CHILDREN'S HOSPITAL BOSTON
|
MA
|
$443,484
|
Anthrax
|
2012
|
NIAID
|
1R01AI098844-01
|
|
Final preclinical development of an immunoadhesin therapy for inhalation anthrax
|
WYCOFF, KEITH
|
PLANET BIOTECHNOLOGY, INC.
|
CA
|
$1,230,830
|
Anthrax
|
2012
|
NIAID
|
1R01AI098884-01
|
|
Development of Enabling Vector/Antigen Expression Technology for an Orally-Delive
|
SIM, B.
|
PROTEIN POTENTIAL, LLC
|
MD
|
$1,411,961
|
Anthrax
|
2012
|
NIAID
|
5R01AI073375-05
|
|
Targeting Bacillus DHFR: Structural Studies and Synthesis of Inhibitors
|
ANDERSON, AMY
|
UNIVERSITY OF CONNECTICUT STORRS
|
CT
|
$326,572
|
Anthrax
|
2012
|
NIAID
|
5U01AI078067-05
|
|
Antidotes to Anthrax Lethal Factor Intoxication
|
JOHNSON, ALAN
|
PANTHERA BIOPHARMA, LLC
|
HI
|
$1,140,279
|
Anthrax
|
2012
|
NIAID
|
5R01AI056324-10
|
|
NLR Family Proteins: Mechanisms and Regulation
|
REED, JOHN
|
SANFORD-BURNHAM MEDICAL RESEARCH INSTIT
|
CA
|
$467,998
|
Anthrax
|
2012
|
NIAID
|
5R42AI062095-05
|
|
Role of Inter-alpha Inhibitors in Anthrax Intoxication
|
OPAL, STEVEN
|
PROTHERA BIOLOGICS, LLC
|
RI
|
$799,975
|
Anthrax
|
2012
|
NIAID
|
5R21AI096087-02
|
|
Mechanism of Anthrax Lethal Factor Toxicity
|
KAYYALI, USAMAH
|
TUFTS MEDICAL CENTER
|
MA
|
$198,750
|
Anthrax
|
2012
|
NIAID
|
5R44AI053005-07
|
|
Novel Therapy for Pulmonary Anthrax
|
WYCOFF, KEITH
|
PLANET BIOTECHNOLOGY, INC.
|
CA
|
$995,532
|
Anthrax
|
2012
|
NIAID
|
5U01AI082081-04
|
|
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway
|
ANTHONY, KAREN
|
L2 DIAGNOSTICS, LLC
|
CT
|
$1,655,184
|
Anthrax
|
2012
|
NIAID
|
5R01AI090685-03
|
|
Broad-spectrum Antifolates for Treatment of Drug Resistant Bacillus anthracis
|
BARROW, WILLIAM
|
OKLAHOMA STATE UNIVERSITY STILLWATER
|
OK
|
$842,854
|
Anthrax
|
2012
|
NIGMS
|
5R01GM029210-34
|
|
Gating of Protein Channels in Lipid Bilayer Membranes
|
FINKELSTEIN, ALAN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
NY
|
$741,016
|
Anthrax
|
2012
|
NIAID
|
5R01AI033537-18
|
|
Virulence Gene Expression by Bacillus anthracis
|
KOEHLER, THERESA
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
TX
|
$295,588
|
Anthrax
|
2012
|
NIGMS
|
1R01GM097357-01A1
|
|
Integrated Methods for Structural Elucidation of Proteins and Macromolecular Comp
|
WILLIAMS, EVAN
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$270,169
|
Anthrax
|
2012
|
NIAID
|
5R01AI083234-04
|
|
Anthrax Toxin Lethal Factor Inhibition Study
|
AMIN, ELIZABETH
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$465,589
|
Anthrax
|
2012
|
NIAID
|
1R21AI096314-01A1
|
|
Bacterial Heme Transport by non-Isd NEAT Proteins
|
MARESSO, ANTHONY
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$234,750
|
Anthrax
|
2012
|
NIGMS
|
5SC1AI081654-05
|
|
Identification of novel mammalian genes required for intoxication by antrax toxin
|
CHAUDRY, G.
|
UNIVERSITY OF TEXAS SAN ANTONIO
|
TX
|
$247,844
|
Anthrax
|
2012
|
NIGMS
|
5R01GM081571-05
|
|
A systems level analysis of spore coat assembly in Bacillus subtilis
|
EICHENBERGER, PATRICK
|
NEW YORK UNIVERSITY
|
NY
|
$299,041
|
Anthrax
|
2012
|
NIAID
|
5U01AI056546-10
|
|
Development and testing of polyvalent anthrax toxin inhibitors
|
MOGRIDGE, JEREMY
|
UNIVERSITY OF TORONTO
|
CANADA
|
$1,278,409
|
Anthrax
|
2012
|
NIAID
|
7U01AI082226-04
|
|
Stimulated Innate Resistance of the Lungs to Bioterror pathogens
|
HOOK, AXEL
|
TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
|
TX
|
$450,594
|
Anthrax
|
2012
|
NIAID
|
5U01AI078169-05
|
|
Development of a Next Generation Anthrax Vaccine, AV7909
|
PARK, SUKJOON
|
EMERGENT BIOSOLUTIONS
|
MD
|
$246,331
|
Anthrax
|
2012
|
NIAID
|
5R01AI083449-04
|
|
Immunobiology of Bacillus anthracis Spore-Host Interactions
|
KEARNEY, JOHN
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$362,588
|
Anthrax
|
2012
|
NIAID
|
5R01AI093418-02
|
|
Point-of-care concentration and detection of pathogen antigens in samples
|
CANGELOSI, GERARD
|
SEATTLE BIOMEDICAL RESEARCH INSTITUTE
|
WA
|
$558,622
|
Anthrax
|
2012
|
NIAID
|
5R01AI093370-03
|
|
Novel multivalent vaccine for anthrax and botulinum
|
MOHAMADZADEH, MANSOUR
|
UNIVERSITY OF FLORIDA
|
FL
|
$678,226
|
Anthrax
|
2012
|
NIAID
|
5R01AI093493-02
|
|
A novel anti-spore nasal vaccine for protection from anthrax
|
DRIKS, ADAM
|
LOYOLA UNIVERSITY CHICAGO
|
IL
|
$663,922
|
Anthrax
|
2012
|
NIAID
|
5R01AI090802-03
|
|
Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select Agen
|
DRUSANO, GEORGE
|
UNIVERSITY OF FLORIDA
|
FL
|
$687,841
|
Anthrax
|
2012
|
NIAID
|
5R21AI095810-02
|
|
Proteomics of RNA polymerase interactomes in pathogenic bacteria
|
NUDLER, EVGENY
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$211,250
|
Anthrax
|
2012
|
NIAID
|
1R21AI101093-01
|
|
Exposporium determinants of Bacillus anthracis
|
STEWART, GEORGE
|
UNIVERSITY OF MISSOURI-COLUMBIA
|
MO
|
$185,287
|
Anthrax
|
2012
|
NIAID
|
1R01AI097167-01A1
|
|
Iron Acquisition in Anthrax
|
MARESSO, ANTHONY
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$391,250
|
Anthrax
|
2012
|
NIAID
|
1R01AI095293-01A1
|
|
Bacillus Anthracis and Complement
|
XU, YI
|
TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
|
TX
|
$364,626
|
Anthrax
|
2012
|
NIAID
|
5U54AI057168-09
|
5659
|
Multiplexed ultra fast and sensitive bioagent assays- Diagnostics
|
GEDDES, CHRISTOPHER
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$286,588
|
Anthrax
|
2012
|
NIAID
|
5U54AI057159-09
|
5568
|
COPI interactions mediate toxin entry: a common shared mechanism of translocation
|
MURPHY, JOHN
|
BOSTON MEDICAL CENTER
|
MA
|
$43,135
|
Anthrax
|
2012
|
NIAID
|
5U19AI057266-09
|
8182
|
Human Monoclonal Antibodies
|
WILSON, PATRICK
|
UNIVERSITY OF CHICAGO
|
IL
|
$587,675
|
Anthrax
|
2012
|
NIAID
|
5U54AI057158-09
|
5678
|
Animal Core
|
PERLIN, DAVID
|
UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL
|
NJ
|
$676,051
|
Anthrax
|
2012
|
NIAID
|
5U54AI057158-09
|
5701
|
Development of new passive immunization strategies for anthrax
|
CASADEVALL, ARTURO
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
NY
|
$905,650
|
Anthrax
|
2012
|
NIAID
|
5U54AI057153-09
|
5860
|
Therapies of infections caused by gram-positive bacteria
|
MISSIAKAS, DOMINIQUE
|
UNIVERSITY OF CHICAGO
|
IL
|
$639,237
|
Anthrax
|
2012
|
NIAID
|
5U54AI057153-09
|
5867
|
Structural basis for selctive lysis of anthrax and drug-resistant S. aureus
|
FISCHETTI, VINCENT
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$367,124
|
Anthrax
|
2012
|
NIAID
|
5U54AI057153-09
|
5872
|
Animal Research and Immunology Core
|
MISSIAKAS, DOMINIQUE
|
UNIVERSITY OF CHICAGO
|
IL
|
$497,500
|
Anthrax
|
2012
|
NIAID
|
5U54AI057153-09
|
5876
|
Staphylococcal superantigen and anthrax inhibitors
|
SCHLIEVERT, PATRICK
|
UNIVERSITY OF MINNESOTA
|
MN
|
$310,731
|
Anthrax
|
2012
|
NIAID
|
5U54AI057156-09
|
6297
|
Administrative Core
|
WALKER, DAVID
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$517,230
|
Anthrax
|
2012
|
NIAID
|
5U19AI062629-09
|
8017
|
Edema Toxin Suppression of Immune Responses During Anthrax Disease
|
BALLARD, JIMMY
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$332,555
|
Anthrax
|
2012
|
NIAID
|
5U19AI062629-09
|
8018
|
Role of B. anthracis Toxins in Human Inhalation Anthrax
|
METCALF, JORDAN
|
UNIVERSITY OF OKLAHOMA
|
OK
|
$368,730
|
Anthrax
|
2012
|
NIAID
|
5U19AI062629-09
|
8019
|
B. anthracis Peptidoglycan as a Pro-inflammatory Agent in Anthrax Pathogenesis
|
COGGESHALL, KENNETH
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$241,536
|
Anthrax
|
2012
|
NIAID
|
5U19AI062629-09
|
8020
|
Characterization of Protective Humoral Anthrax Immunity
|
JAMES, JUDITH
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$340,119
|
Anthrax
|
2012
|
NIAID
|
5U19AI062629-09
|
8021
|
Reverse Genomics of Anti-Protective Antigen Responses
|
HARLEY, JOHN
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$282,787
|
Anthrax
|
2012
|
NIAID
|
5U19AI062629-09
|
8069
|
Translation of immunologic technologies from basic research into pre-clinical non
|
KUROSAWA, SHINICHIRO
|
BOSTON UNIVERSITY
|
MA
|
$401,462
|
Anthrax
|
2012
|
NIAID
|
5U19AI062629-09
|
8071
|
Early Plasma Cells as a Source of Anthrax-Neutralizing Antibodies
|
WILSON, PATRICK
|
UNIVERSITY OF CHICAGO
|
IL
|
$333,451
|
Anthrax
|
2012
|
NIAID
|
5U19AI062629-09
|
8072
|
Educational Component
|
FARRIS, A. DARISE
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$58,671
|
Anthrax
|
2012
|
NIAID
|
5U19AI062629-09
|
8074
|
Administration Core
|
COGGESHALL, KENNETH
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$134,504
|
Anthrax
|
2012
|
NIAID
|
5U19AI062629-09
|
8075
|
Pilot Project Program
|
BALLARD, JIMMY
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$142,591
|
Anthrax
|
2012
|
NIAID
|
5U19AI062629-09
|
8076
|
Scientific Core: Flow Cytometry and Sorting Core Facility
|
KINCADE, PAUL
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$56,564
|
Anthrax
|
2012
|
NIAID
|
5U19AI062629-09
|
8078
|
Scientific Core: Bacillus anthracis Anthrax Toxin Core
|
BALLARD, JIMMY
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$83,802
|
Anthrax
|
2012
|
NIAID
|
1R21AI102223-01
|
|
Host Vascular Mechanism for Therapeutic Protection against Select Pathogens
|
CHAN, JOANNE
|
CHILDREN'S HOSPITAL BOSTON
|
MA
|
$246,732
|
Anthrax
|
2012
|
NIAID
|
1R43AI102294-01
|
|
Development of a simple and effective therapy against post-exposure anthrax
|
ZHANG, JIANFENG
|
VAXIN INC.
|
MD
|
$110,701
|
Anthrax
|
2012
|
NIAID
|
2R44AI090719-03
|
|
Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic
|
JARVIS, THALE
|
CRESTONE, INC.
|
CO
|
$1,000,000
|
Anthrax
|
2012
|
NIAID
|
272201000036C-3-0-1
|
|
Development of Technologies to Facilitate the use and Response of Vaccines
|
GURWITH, MARC
|
PAXVAX, INC.
|
CA
|
$1,651,037
|
Anthrax
|
2012
|
NCI
|
261200800001E-51-0-3
|
|
DCTD Computer Support
|
HEIMBROOK, DAVID
|
SAIC-FREDERICK, INC.
|
MD
|
$1,986,559
|
Anthrax
|
2012
|
NIAID
|
N01AI30063-66-0-4
|
|
Task 01: Development of Antibiotics for Anthrax
|
NO PI IDENTIFIED
|
SOUTHERN RESEARCH INSTITUTE
|
AL
|
$285,000
|
Anthrax
|
2012
|
NIAID
|
3R01AI033537-18S1
|
|
Virulence Gene Expression by Bacillus anthracis
|
KOEHLER, THERESA
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
TX
|
$85,120
|
Anthrax
|
2012
|
NIAID
|
272200700058C-4-0-1
|
|
Structural Genomics Centers for Infectious Diseases
|
ANDERSON, WAYNE
|
NORTHWESTERN UNIVERSITY
|
IL
|
$584,214
|
Anthrax
|
2012
|
NIAID
|
AAI12014001-1-0-1
|
|
Models of Inhalational Anthrax for Evaluating the Efficacy of Therapeutics
|
NO PI IDENTIFIED
|
NIH
|
|
$1,008,145
|
Anthrax
|
2012
|
NIAID
|
272200800038C-5-0-1
|
|
Adjuvant Development Program
|
LANGE, LAURA
|
DYNAVAX TECHNOLOGIES CORPORATION
|
CA
|
$2,248,871
|
Anthrax
|
2012
|
NIAID
|
272201000035C-4-0-1
|
|
Development of Technologies to Facilitate the Use of and Response to Vaccines
|
LEMIALE, LAURENCE
|
EMERGENT BIOSOLUTIONS
|
MD
|
$14,455,413
|
Anthrax
|
2012
|
NIAID
|
272201100012I-0-27200002-1
|
|
Task A04: In Vitro Assessments of Antibacterial Activity
|
NO PI IDENTIFIED
|
SOUTHERN RESEARCH INSTITUTE
|
AL
|
$139,585
|
Anthrax
|
2012
|
NIDDK
|
1ZIADK059701-39
|
|
Reactions And Immunochemistry Of Carbohydrates
|
KOVAC, PAVOL
|
NIH
|
|
$781,187
|
Anthrax
|
2012
|
NIEHS
|
1ZIAES050127-20
|
|
Application Of Mass Spectrometry To Structural Biology
|
TOMER, KENNETH
|
NIH
|
|
$199,445
|
Anthrax
|
2012
|
NIEHS
|
1ZIAES050171-13
|
|
Protein Characterization By Mass Spectrometry
|
TOMER, KENNETH
|
NIH
|
|
$445,513
|
Anthrax
|
2012
|
NICHD
|
1ZIAHD008779-08
|
|
Peptide-Protein Conjugate Vaccines
|
SCHNEERSON, RACHEL
|
NIH
|
|
$381,818
|
Anthrax
|
2012
|
NICHD
|
1ZIAHD008839-06
|
|
Development of vaccines to bacterial diseases found especially in children
|
ROBBINS, JOHN
|
NIH
|
|
$2,243,180
|
Anthrax
|
2012
|
NIDDK
|
1ZICDK070011-06
|
|
Production , purification and preparation of various candidiate vaccines
|
SHILOACH, JOSEPH
|
NIH
|
|
$315,595
|
Anthrax
|
2012
|
NIAID
|
1ZIAAI000929-10
|
|
Vaccines and Therapeutics for Anthrax
|
LEPPLA, STEPHEN
|
NIH
|
|
$928,890
|
Anthrax
|
2012
|
NIAID
|
1ZIAAI000936-09
|
|
Pathogenesis, Treatment and Prevention of Emerging Infectious Diseases
|
LANE, HENRY
|
NIH
|
|
$171,956
|
Anthrax
|
2012
|
NIAID
|
1ZIAAI000984-06
|
|
Influenza and Emerging Infectious Diseases
|
DAVEY, RICHARD
|
NIH
|
|
$1,840,538
|
Anthrax
|
2012
|
NIAID
|
1ZIAAI001016-06
|
|
New Approaches To Passive Immunoprophylaxis
|
PURCELL, ROBERT
|
NIH
|
|
$426,742
|
Anthrax
|
2012
|
NIAID
|
1ZIAAI001030-05
|
|
Molecular Genetics and Pathogenesis of Anthrax
|
LEPPLA, STEPHEN
|
NIH
|
|
$541,170
|
Anthrax
|
2012
|
NIAID
|
1ZIAAI001031-05
|
|
Structure and Function of Virulence Factors of Bacillus anthracis
|
LEPPLA, STEPHEN
|
NIH
|
|
$541,170
|
Anthrax
|
2012
|
NIAID
|
1ZIAAI001032-05
|
|
Pathophysiological Actions of Anthrax Virulence Determinants
|
LEPPLA, STEPHEN
|
NIH
|
|
$676,462
|
Anthrax
|
2012
|
NIAID
|
272201200032C-0-0-1
|
|
Technologies to Advance Next Generation Anthrax Vaccines
|
TRANRER, HOWARD
|
HEALTH PROTECTION AGENCY
|
UK
|
$6,501,809
|
Anthrax
|
2012
|
NIAID
|
272201200033C-0-0-1
|
|
Technologies to Advance Next Generation Anthrax Vaccines
|
SQUIRES, CHUCK
|
PFENEX, INC.
|
CA
|
$2,180,144
|
Anthrax
|
2012
|
NIAID
|
272201200034C-0-0-1
|
|
Technologies to Advance Next Generation Anthrax Vaccines
|
YUSIBOV, VIDADI
|
CENTER FOR EXPERMENTAL SOFTWARE ENGR MD
|
MD
|
$1,760,014
|
Anthrax
|
2012
|
NIAID
|
272201200026C-1-0-2
|
|
STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES
|
ANDERSON, WAYNE
|
NORTHWESTERN UNIVERSITY
|
IL
|
$1,469,460
|
|